In-silico screening and molecular docking studies of active constituents of Withania somnifera to investigate its kinase inhibitory activities

Background: Withania somnifera popularly known as Ashwagandha is a popular herbal medicine exhibits anti-cancer,anti-oxidant, anti-inflammatory, anti-stress, anti-tumour, haemopoietic andimmunomodulatory activity. Withania somnifera is used as a chemotherapeutic agent for cancertherapy. Kinases play important role in the different types of cancerprogressionmainly in carcinogenesis and metastasis, elucidated by understanding the basic molecular mechanisms of signalling of the cancer cell. Materials and methods:The purpose of the study was to summarise the kinase inhibitory potential of active constituents of ashwagandha by in-silico analysis. The in-silico methods used in the study are Lipinski's rule of five, evaluation of in-silicotoxicity by admetSAR, analysis of electronic parameters and ADME properties and molecular docking using Schrodinger 2018-3 suit device Maestro 11.7.02 software.Thekinase targets considered in the study were CDK4, CDK6, EGFR, and VEGFR (PDB I.D: 5L2S,6P8E,7JXQ, and 4AGC). Results: On the basis of the results of in-silico analysis, most of the constituents of ashwagandha exhibited good kinase inhibitory activity, out of which Withanolide A, Anaferin, Withaferin A and Withoxylactone were found to show strong inhibition for CDK6, EGFR, CDK4 and VEGFR respectively. Out of four target kinases, CDK6 and EGFR was found to be the better target for the constituents of Ashwagandha.